Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Von Willebrand factor C domain containing 2 (VWC2) is a secreted protein primarily known as a bone morphogenetic protein antagonist, regulating BMP signaling in the extracellular space. It is involved in neural development, cell adhesion, and may play a role in bone formation and differentiation. VWC2 is part of a family of proteins containing the von Willebrand factor type C domain, which provides versatile binding characteristics for protein-protein interactions in development and pattern formation. Its function as a BMP antagonist positions it as a regulatory molecule rather than a classical receptor or enzyme, impacting growth factor signaling cascades relevant to skeletal and neural development.
BMP antagonist: inhibits signaling of bone morphogenetic proteins via competitive binding, particularly BMP-2 and BMP-6, affecting receptor interaction and downstream signaling. Modulation of extracellular signaling complexes affecting neural and bone development pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Von Willebrand factor C domain containing 2 (VWC2).